BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Wednesday, July 9, 2025 at 8:00 a.m. ET to disclose topline results from the randomized, placebo-controlled portion of the Phase 2 trial evaluating bivamelagon, an investigational... Read more
Bagsværd, Denmark, 8 July 2025 – Novo Nordisk today announced the submission of an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy® (subcutaneous semaglutide 7.2 mg). This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity, as part of their journey towards better health. The... Read more
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CALIFORNIA / ACCESS Newswire / June 30,... Read more
Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA) today announced new animal study results from SKNY-1, a next-generation oral therapeutic under definitive agreement for acquisition. In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and... Read more
No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1 MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment... Read more
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new self-paying patients previously... Read more
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss... Read more
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide... Read more
During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body weight regain by 46% and completely prevented fat regain compared to placebo The enobosarm treated groups showed up to 93% greater fat loss and 100% lean mass preservation compared to the placebo group at the end of the... Read more
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24,... Read more
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates... Read more
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Ef... Read more
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the margin of error for daily weight measurement), compared to expected 5–6% weight regain (10–15 pounds) after stopping GLP-1 therapy Revita continued to demonstrate excellent tolerability profile compared to GLP-1 drugs;... Read more
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of... Read more
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40 in a key secondary endpoint The safety profile of orforglipron was consistent with the established GLP-1 class INDIANAPOLIS, June 21, 2025 /PRNewswire/ -- Eli Lilly and Company... Read more
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo1 Safety and tolerability of the higher dose of Wegovy® (semaglutide... Read more
Patients receiving apitegromab with tirzepatide over 24 weeks showed a 54.9% preservation of lean mass (+4.2 lbs of lean mass) versus tirzepatide alone (p=0.001) Patients receiving apitegromab with tirzepatide over 24 weeks lost 18.8 lbs of fat mass while those on tirzepatide alone lost 17.7 lbs of fat mass Patients receiving apitegromab with tirzepatide over 24 weeks lost 12.3% of body weight while those on tirzepatide alone lost 13.4% of body weight Higher quality... Read more
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I study initiation in obese, otherwise healthy volunteers anticipated late 2025 REDWOOD CITY, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq:... Read more
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada’s GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence... Read more
GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders,... Read more
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under Zepbound Self Pay Journey Program In a clinical trial, adults with obesity or overweight and a weight-related medical condition taking Zepbound 15 mg lost 48 lbs (~21% weight loss) and approximately 1 in 3 on Zepbound 15 mg lost over 58 lbs (25% weight loss) INDIANAPOLIS, June 16, 2025 /PRNewswire/... Read more
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. “We are very pleased that the feedback from... Read more
ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue Study initiation highlights Arrowhead’s leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform In preclinical studies, ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to... Read more
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term health TARRYTOWN,... Read more
Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide alone – while also increasing loss of fat mass TARRYTOWN, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced interim results from the ongoing Phase 2 COURAGE trial... Read more
IND submission planned for mid-2025 with Phase 1 SAD data anticipated by year end BGE-102 induced weight loss in preclinical obesity models, both as monotherapy and in combination with GLP-1 receptor agonists Internally discovered compound has a novel binding site and potential best-in-class profile supporting once daily dosing EMERYVILLE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company... Read more
With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions New, one-time $199 first-month offer for Wegovy® available through June 30, 2025; offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff... Read more
Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible New offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per prescription while ensuring clinical safety for patients ST LOUIS, May 21, 2025 /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy... Read more
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary data in 2026, pending CTA authorization BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company pioneering pattern-breaking treatments for obesity... Read more
Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circumference reduction INDIANAPOLIS, May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1... Read more
Use of AI and machine learning accelerates identification of patient groups whose care can be improved First study examines pro-inflammatory TNF-α levels in patients receiving GLP-1 agonists including Wegovy® or Ozempic® Initial findings support opportunities to improve diagnosis and treatment and demonstrate isomyosamine’s potential to impact quality of life in a general practice population BALTIMORE / May 08, 2025 / Business Wire / TNF Pharmaceuticals, Inc.... Read more
WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC Inhibitor IC 100. CEO Stephen C. Glover issued a shareholder letter detailing the company's strategy to position IC 100 as a complementary therapy to GLP-1 agonists to treat obesity-associated cardiometabolic... Read more
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and accelerate discovery of novel drug targets in patients who are unresponsive to therapies SAN DIEGO, May 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today... Read more
HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported the achievement of a third milestone from recent preclinical studies of BP1001-A that provide additional support for its potential as a treatment for obesity. These studies showed BP1001-A rescues... Read more
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- iBio (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting Activin E, which was discovered using iBio’s patented Machine-Learning Antibody Engine. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity... Read more
COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and neurodegenerative diseases COYA 303 produced a statistically significantly higher Treg suppressive effect on pro-inflammatory myeloid cells and enhanced Treg survival in in vitro human immune cells, compared to the individual components - LD... Read more
Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight by an average 16.0 lbs (7.9%) at the highest dose in a key secondary endpoint The overall safety and tolerability profile of orforglipron in ACHIEVE-1 was consistent with injectable GLP-1 therapies INDIANAPOLIS, April 17, 2025 /PRNewswire/ -- Eli Lilly and... Read more
Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety Bremelanotide matched or exceeded tirzepatide in appetite suppression Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation CRANBURY, N.J., April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines... Read more
GLP-1 comparable efficacy: Opaganib's positive results, newly published in the journal Diabetes, Metabolic Syndrome and Obesity, demonstrated weight loss and improved metabolic markers on par with semaglutide in preclinical models Novel mechanism of action, formulation and administration: Opaganib is a differentiated oral, non-peptide therapeutic that targets sphingosine kinase-2 (SPHK2), potentially avoiding common Glucagon-like peptide-1 (GLP-1) inhibitor side effects... Read more
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity model New in vitro data demonstrates superior potency of nimacimab’s differentiated and favorable mechanism of inhibition versus monlunabant Nimacimab Phase 2a CBeyond™ top-line randomized data expected late Q3/early Q4 2025 SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE)... Read more
NEW YORK / Apr 14, 2025 / Business Wire / Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management. Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver... Read more
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“the Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive early data... Read more
Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases... Read more
DUBLIN and BRIDGEWATER, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial cells. “The data presented at ACC.25 continue to underscore the... Read more
Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). Primary analysis for the co-administered group in the 8-week treatment study showed: 40% of patients achieved 5% reduction in weight (p<0.05). 27% achieved 6% reduction in weight (p<0.05). 19% achieved 7% reduction in weight (p<0.1). Low dose&nb... Read more
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial1. Data were presented at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US, while simultaneously published today in New England Journal of Medicine2. Rybelsus®, the only approved oral GLP-1 medicine, demonstrated this risk... Read more
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant SAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a... Read more
RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence Both groups demonstrated comparable weight loss with less variability observed with RT-114 compared to subcutaneous PG-102 Phase 1 clinical trial of subcutaneous PG-102 demonstrated weight loss in obese patients, with an average reduction of 4.8% and up to 8.7% following five... Read more
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset,... Read more
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development for chronic weight management designed to guarantee medication adherence and potentially improve treatment... Read more
